Cargando...

(86)Y based PET radiopharmaceuticals: radiochemistry and biological applications

Development of targeted radionuclide therapy with (90)Y labeled antibodies and peptides has gained momentum in the past decade due to the successes of (90)Y-ibritumomab tiuxetan and (90)Y-DOTA-Phe(1)-Tyr(3)-octreotide in treatment of cancer. (90)Y is a pure β(−)-emitter and cannot be imaged for pati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nayak, Tapan K., Brechbiel, Martin W.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3184346/
https://ncbi.nlm.nih.gov/pubmed/21711222
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!